Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
5
BIOX Quote, Financials, Valuation and Earnings
Last price:
$3.78
Seasonality move
:
-4.13%
Day range:
$3.79 - $3.91
52-week range:
$3.51 - $11.78
Dividend yield:
0%
P/E ratio:
312.90x
P/S ratio:
0.63x
P/B ratio:
0.74x
Volume:
41.5K
Avg. volume:
128.2K
1-year change:
-66.96%
Market cap:
$229.8M
Revenue:
$464.8M
EPS (TTM):
-$0.15
Analysts' Opinion
-
Consensus RatingBioceres Crop Solutions has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $7.38, Bioceres Crop Solutions has an estimated upside of 93.57% from its current price of $3.81.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.00 representing -57.48% downside risk from its current price of $3.81.
Fair Value
-
According to the consensus of 4 analysts, Bioceres Crop Solutions has 93.57% upside to fair value with a price target of $7.38 per share.
BIOX vs. S&P 500
-
Over the past 5 trading days, Bioceres Crop Solutions has underperformed the S&P 500 by -15.57% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Bioceres Crop Solutions does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bioceres Crop Solutions revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Bioceres Crop Solutions reported revenues of $59.6M.
Earnings Growth
-
Bioceres Crop Solutions has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Bioceres Crop Solutions reported earnings per share of -$0.02.
Enterprise value:
483.5M
EV / Invested capital:
--
Price / LTM sales:
0.63x
EV / EBIT:
69.58x
EV / Revenue:
1.26x
PEG ratio (5yr expected):
--
EV / Free cash flow:
17.32x
Price / Operating cash flow:
8.59x
Enterprise value / EBITDA:
15.68x
Gross Profit (TTM):
$151.5M
Return On Assets:
-1.09%
Net Income Margin (TTM):
-2.36%
Return On Equity:
-2.61%
Return On Invested Capital:
-1.5%
Operating Margin:
-9.98%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $415.9M | $445.6M | $383.3M | $84M | $59.6M | |
| Gross Profit | $176.4M | $174.4M | $151.5M | $42.5M | $23.5M | |
| Operating Income | $57.7M | $37.3M | $16.7M | $12.5M | -$5.9M | |
| EBITDA | $67.9M | $53M | $30.8M | $20.5M | $6.6M | |
| Diluted EPS | $0.21 | $0.01 | -$0.15 | $0.14 | -$0.02 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $193.8M | $297M | $421.2M | $407.2M | $338.2M | |
| Total Assets | $361.2M | $503.6M | $846.8M | $836.1M | $798.2M | |
| Current Liabilities | $157.1M | $255.1M | $302.8M | $333M | $332.3M | |
| Total Liabilities | $282.8M | $386.5M | $512.5M | $487.6M | $453.2M | |
| Total Equity | $78.4M | $117.1M | $334.3M | $348.5M | $345M | |
| Total Debt | $183.4M | $205M | $250.1M | $242.8M | $256.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $5.7M | $10M | $46.4M | -$17.4M | $23.3M | |
| Cash From Investing | -$23.9M | -$31.7M | -$7.9M | -$1.4M | -$2.5M | |
| Cash From Financing | $31.2M | -$12.1M | -$19.7M | $10.9M | -$12.7M | |
| Free Cash Flow | -$12.3M | -$13.3M | $27.9M | -$23.4M | $20.2M | |
BIOX
Sector
Market Cap
$229.8M
$19.1M
Price % of 52-Week High
32.34%
70.42%
Dividend Yield
0%
0%
Shareholder Yield
-2.11%
0.73%
1-Year Price Total Return
-66.96%
-6.33%
Beta (5-Year)
0.413
0.736
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$4.23
200-day SMA
Sell
Level
$5.63
Bollinger Bands (100)
Sell
Level
4.18 - 4.82
Chaikin Money Flow
Sell
Level
-2M
20-day SMA
Sell
Level
$4.49
Relative Strength Index (RSI14)
Sell
Level
33.42
ADX Line
Sell
Level
16.93
Williams %R
Buy
Level
-98.3471
50-day SMA
Sell
Level
$4.60
MACD (12, 26)
Sell
Level
-0.17
25-day Aroon Oscillator
Sell
Level
-80
On Balance Volume
Neutral
Level
1.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.5864)
Sell
CA Score
(Annual)
Level (-0.6708)
Buy
Beneish M-Score
(Annual)
Level (-2.3616)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (3.5704)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bioceres Crop Solutions Corp is a fully integrated provider of crop productivity solutions, including seeds, seed traits, seed treatments, biologicals, high-value adjuvants, and fertilizers. The company has developed a multi-discipline and multi-product platform capable of providing solutions throughout the entire crop cycle, from pre-planting to transportation and storage. Some of the products offered by the company include fertilizers, inoculants, adjuvants, crop protection solutions, and seeds among others. Its operating segments are crop protection, which derives key revenue, seed and integrated products, and crop nutrition. Geographically, the majority of the company's revenue is generated from Argentina and the rest from Brazil, North America, Latin America, and other regions.
Stock Forecast FAQ
In the current month, BIOX has received 4 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BIOX average analyst price target in the past 3 months is $7.38.
-
Where Will Bioceres Crop Solutions Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bioceres Crop Solutions share price will rise to $7.38 per share over the next 12 months.
-
What Do Analysts Say About Bioceres Crop Solutions?
Analysts are divided on their view about Bioceres Crop Solutions share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bioceres Crop Solutions is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is Bioceres Crop Solutions's Price Target?
The price target for Bioceres Crop Solutions over the next 1-year time period is forecast to be $7.38 according to 4 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BIOX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bioceres Crop Solutions is a Buy. 4 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BIOX?
You can purchase shares of Bioceres Crop Solutions via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bioceres Crop Solutions shares.
-
What Is The Bioceres Crop Solutions Share Price Today?
Bioceres Crop Solutions was last trading at $3.78 per share. This represents the most recent stock quote for Bioceres Crop Solutions. Yesterday, Bioceres Crop Solutions closed at $3.81 per share.
-
How To Buy Bioceres Crop Solutions Stock Online?
In order to purchase Bioceres Crop Solutions stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
